How to Help Your Patients Find Adenocard (Adenosine) in Stock: A Provider's Guide

Adenocard (adenosine injection) is one of those critical medications that providers rarely think about sourcing — until it is not there when they need it. Whether you are an emergency physician, cardiologist, intensivist, or nuclear medicine physician, a sudden inability to locate adenosine injection at your facility creates both clinical and administrative urgency.

This guide is for providers and clinical teams who need a structured process for locating adenosine when supply runs low — including practical tools, distributor strategies, and how to leverage medication-finding resources efficiently.

Understanding the Supply Chain for Adenosine Injection

Unlike oral medications that flow through retail pharmacy channels, adenosine injection is an institutional drug purchased through group purchasing organizations (GPOs) and medical-surgical distributors. The typical supply chain looks like this:

1. Manufacturer (Pfizer, Hikma, Fresenius Kabi, etc.) →
2. Primary Wholesaler (Cardinal Health, McKesson, AmerisourceBergen) →
3. GPO Contract (Premier, Vizient, HealthTrust) →
4. Hospital Pharmacy → Clinical Use

When a disruption occurs at the manufacturer or wholesaler level, the pharmacy buyer is often the first to notice — typically when a standard order comes back with an allocation limit or back-order notice. This is the first signal to begin a proactive search across alternative sources.

Step-by-Step Guide for Locating Adenosine When Supply Is Tight

Step 1: Cross-reference all available NDC numbers.

Adenosine 3 mg/mL is available under multiple NDC numbers from different manufacturers. Ask your pharmacy buyer to pull availability across all NDCs in your GPO's catalog and on secondary distributor platforms. One manufacturer's product may be in stock even if your usual source is backordered.

Step 2: Contact secondary wholesalers directly.

Secondary and spot-market wholesalers often carry inventory that primary GPO sources cannot fulfill. Examples include Andover Medical, American Surgical & Medical Supply, and various regional secondary distributors. Always verify NABP VAWD accreditation before purchasing from any secondary source.

Step 3: Check ASHP and FDA databases for shortage intelligence.

The ASHP Drug Shortage Database (ashp.org/drug-shortages) and FDA Drug Shortage Database (accessdata.fda.gov) provide the most authoritative real-time shortage information. If adenosine appears in either database, check which specific presentations (vial size, NDC) are affected and which manufacturers are still producing.

Step 4: Use medfinder.

medfinder contacts pharmacies and distributors near your facility to find which ones have adenosine injection in stock. For providers managing supply challenges across multiple clinical sites, medfinder for providers streamlines the search process and delivers results directly — eliminating the time-consuming process of calling each source manually.

Step 5: Coordinate with peer institutions.

Within a health system, your pharmacy director should communicate with sister facilities about adenosine stock levels. Independent hospitals can also reach out informally to regional peers. Pharmacy-to-pharmacy transfers are a recognized practice during drug shortages and can provide a critical bridge while your formal order is fulfilled.

Institutional vs. Retail Pharmacy Channels — What Is the Difference?

Adenosine injection is not dispensed at retail pharmacies. It is an institutional medication purchased in bulk by healthcare facilities. This distinction matters when providers are searching: do not direct patients to call CVS or Walgreens — those pharmacies do not carry IV adenosine. The search should focus on hospital pharmacies, compounding pharmacies (503B outsourcing facilities), and medical distributors.

How to Communicate Supply Challenges to Patients

For scheduled pharmacologic stress tests that need to be rescheduled or adapted due to adenosine availability, providers should:

• Contact patients proactively — do not wait for the day of the appointment
• Explain that regadenoson (Lexiscan) is a medically equivalent alternative and that the diagnostic quality of their test will not be compromised
• Provide a realistic timeline — if you expect supply to be resolved within a week, give patients that context
• For patients with PSVT history: reassure them that emergency protocols are in place, and the team is prepared with alternative agents if needed

Documentation and Quality Reporting During Shortages

When your facility activates shortage protocols, thorough documentation protects your team and ensures continuity of care. Document the shortage date, which alternative agent was used, the clinical rationale, and patient outcomes. This data is also valuable for quality reporting and for communicating the clinical impact to GPOs and manufacturers — helping drive systemic supply chain improvements.

Key Resources for Providers

For a comprehensive clinical guide to managing adenosine shortages including detailed alternative drug protocols, see our article: Adenocard Shortage: What Providers and Prescribers Need to Know in 2026. Additional resources:

• ASHP Drug Shortage Center: ashp.org/drug-shortages
• FDA Drug Shortage Database: accessdata.fda.gov/scripts/drugshortages
• AHA ACLS Guidelines for SVT management
• medfinder for providers: medfinder.com/providers